Augustine Therapeutics, a Belgian biotech, has appointed Sylvain Celanire as chief executive to lead the development of new medicines for neurodegenerative diseases. Dr Celanire holds a PhD in medicinal chemistry from the University of Rouen in France and started his career at UCB New Medicines in Belgium. He subsequently joined Addex Therapeutics in Switzerland before co-founding Pragma Therapeutics in France. Pragma is developing medicines for sensory-neural hearing loss and neuropsychiatric disorders. Most recently, Dr Celanire has worked as a consultant to private and listed biotech companies.
Augustine Therapeutics announced the appointment on 18 March 2021.
Copyright 2021 Evernow Publishing Ltd